BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BC-3781: Phase II data

Data from 165 clinically evaluable patients in a double-blind, U.S. Phase II trial showed that twice-daily 100 and 150 mg IV BC-3781 produced comparable clinical cure rates at the TOC visit 7-14 days after the end of treatment, the primary endpoint, to that of IV vancomycin (91% and 89%, respectively, vs. 92%)....

Read the full 238 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >